Wall Street is positive on Aridis Pharmaceuticals Inc (ARDS). On average, analysts give Aridis Pharmaceuticals Inc a Strong Buy rating. The average price target is $17, which means analysts expect the stock to climb by 226.30% over the next twelve months. That average ranking earns Aridis Pharmaceuticals Inc an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ARDS a Strong Buy today. Find out what this means to you and get the rest of the rankings on ARDS!